Pharmacologic Interventions for Dementia Syndromes will explore intervention with an emphasis on using the published literature to choose pharmacological interventions for cognitive and behavioral manifestations of dementia, including the roles (i.e., indications and benefits), cautions (i.e., risks, side-effects, warnings) and potential alternatives to using cholinesterase inhibitors, memantine, antipsychotics, and antidepressants in ADRD. Finally, given the recent FDA approval of 3 amyloid imaging agents, this program will also help participants better understand how biomarkers are changing practices with regard to clinical research and management of ADRD.
Howard Aizenstein, MD, PhD,
Professor of Psychiatry
Associate Professor of Bioengineering, and Clinical and Translational Science
University of Pittsburgh School of Medicine
- Identify treatment targets used for Alzheimer’s Disease (AD)
- Examine current pharmacotherapy for enhancing cognition
- Assess pharmacotherapy for behavioral complications of AD
- Discuss disease modifying agents on the horizon
Contact Hours: 1.5
This activity provides professional development for licensed nurses and social workers. Social Work CE is made possible by a collaboration with the Pitt School of Social Work’s Continuing Education Department.
Note: 1.5 contact hours may be used as Pharmacotherapeutic
Program supported by Health Resources and Services Administration Grant # U1QHP28736
Review Date: September 14, 2022